Fortrea

Fortrea

Life Sciences Tools & Services
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

$2.1B

Market Cap • 10/30/2026

2023

(3 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,9

P/S

0,8

P/EBITDA

22,5

P/OCF

10,2

P/FCF

12,2

P/E

—

BVPS

5,5

EPS

—

Market Cap

Market Cap

2,1B

EV

3B

EV/Revenue

1,1

EV/EBITDA

32,3

EV/EBIT

230,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-1,4B

Profitability

Gross Margin

20%

EBITDA Margin

3,4%

EBIT Margin

—

Net Margin

—

D&A/EBITDA

86%

R&D/Revenue

0%

Capex/Revenue

1,2%

Capex/D&A

41,7%

Capex/OCF

16,3%

SBC/OCF

25,2%

% PPE

5,8%

% Goodwill

34,7%

ROE

—

ROIC

—

Leverage

N.D./EBITDA

9,8

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,9

Interest Coverage

15,6%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium